ARQT - Arcutis Biotherapeutics, Inc.
About Arcutis Biotherapeutics, Inc. (https://www.arcutis.com)
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Todd Franklin Watanabe | President, Chief Executive Officer & Director | 1968 | $1,306,917 USD |
| L. Todd Edwards | Executive Vice President & Chief Commercial Officer | 1964 | $897,205 USD |
| Patrick E. Burnett | Executive Vice President & Chief Medical Officer | 1972 | $883,376 USD |
| Masaru Matsuda | Executive VP, Chief Legal Officer & Corporate Secretary | 1971 | $787,699 USD |
| Latha Vairavan | Senior Vice President & Chief Financial Officer | 1978 | $644,904 USD |
| Bhaskar Chaudhuri | Co-Founder & Director Emeritus | 1955 | $60,054 USD |
| Aleen Hosdaghian | Vice President of Marketing | – | – |
| Amanda Sheldon | Head of Corporate Communications | – | – |
| Brian Schoelkopf | Head of Investor Relations | – | – |
| Steve Arias | Vice President of Compliance & Privacy | – | – |